2023-506997-11-00招募中1 期
A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers.
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 14
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
AstraZeneca Clinical Study Information Center
Scientific
Astrazeneca AB
研究点 (4)
Loading locations...
相似试验
招募中
1 期
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
招募中
1 期
Single and multiple ascending dose of ZP9830 in healthy participants2023-509929-51-00Zealand Pharma A/S92
已完成
1 期
A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment And is not Responsive After Treatment.2023-506564-14-00Celgene International II S.a.r.l.112
招募中
1 期
Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of intravenous single ascending doses of IM-250 in healthy volunteers.Herpes simplex virus encephalitis2025-523146-27-00Innovative Molecules GmbH30
招募中
2 期
A trial to learn how safe AZD3632 is, how well it works, and how it moves throughout the body over time in adults with acute leukemia and myelodysplastic syndrome with HOX gene overexpression2025-521299-76-00AstraZeneca AB1